Table 2.

Summary of the change in clinical parameters in the T&E and mT&E groups between baseline and 36 months

	T&E group (n=135 eyes)	mT&E group (n=119 eyes)	P value*
Increase in BCVA of ≥15 ETDRS letters, n (%)	31 (23)	30 (25.2)	0.39
Decrease in BCVA of ≥15 ETDRS letters, n (%)	29 (21.5)	21 (17.7)	0.43
No of injections per year, mean±SD	7.9±2.9	8.1±2.3	0.55
Change in CPT, median (IQR)	−106 (185.0)	−69.5 (133.3)	0.61
Change in CST, median (IQR)	−65 (136.5)	−56 (146.25)	0.55
No fluid at the final visit, n (%)	36 (26.7)	45 (37.8)	0.06

*Calculated using Student’s t-test, Wilcoxon signed-rank test or Fisher’s exact test.

BCVA, best-corrected visual acuity; CPT, central point thickness; CST, central subfield thickness; ETDRS, Early Treatment for Diabetic Retinopathy Study; mT&E, modified treat-and-extend; T&E, treat-and-extend.